澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BOTANIX PHARMACEUTICALS LTD

0.023

+0.0029.52%

成交量：828.08萬

成交額：18.49萬

市值：6,288.92萬

市盈率：-0.50

高：0.023

開：0.021

低：0.021

收：0.021

52周最高：0.350

52周最低：0.020

股本：27.34億

流通股本：17.18億

量比：0.75

換手率：0.48%

股息：- -

股息率：- -

每股收益(TTM):-0.046

每股收益(LYR):-0.047

淨資產收益率：-121.11%

總資產收益率：-53.38%

市淨率：1.16

市盈率(LYR):-0.49

資料載入中...

總覽公司新聞資訊公告

皮拉馬爾製藥解決方案宣佈與Botanix合作，支持藥物原料開發

Botanix製藥與Piramal達成合作後者將啓動Sofdra活性成分溴化索夫溴銨的開發服務並擔任替代商業供應商

Botanix製藥公司獲得4000萬澳元兩輪增發堅定承諾，新股發行價每股0.06澳元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BOT.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.023,"timestamp":1781244720000,"preClose":0.021,"halted":0,"volume":8280767,"delay":0,"changeRate":0.09523809523809515,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1717605114,"shares":2734312800,"eps":-0.046233,"marketStatus":"未開盤","change":0.002,"latestTime":"06-12 16:12:00 AEST","open":0.021,"high":0.023,"low":0.021,"amount":184891,"amplitude":0.095238,"askPrice":0.023,"askSize":70000,"bidPrice":0.022,"bidSize":995500,"shortable":3,"etf":0,"ttmEps":-0.046233,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1781481600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.021,"openAndCloseTimeList":[[1781222400000,1781244000000]],"volumeRatio":0.7469834047261628,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BOT.AU","preClose":0.021,"auctionPrice":0.023,"auctionVolume":522000,"auction":3,"marketStatus":"盘后竞价","timestamp":1781244600644}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1717605114,"roa":"-53.38%","roe":"-121.11%","lyrEps":-0.046827,"volumeRatio":0.7469834047261628,"shares":2734312800,"dividePrice":0,"high":0.023,"amplitude":0.095238,"preClose":0.021,"low":0.021,"week52Low":0.02,"pbRate":"1.16","psRate":"2.87","week52High":0.35,"institutionHeld":0,"latestPrice":0.023,"committee":0.868606,"eps":-0.046233,"divideRate":0,"volume":8280767,"delay":0,"ttmEps":-0.046233,"open":0.021,"prevYearClose":0.135,"prevWeekClose":0.023,"prevMonthClose":0.024,"prevQuarterClose":0.042,"fiveDayClose":0.022,"twentyDayClose":0.029,"sixtyDayClose":0.047},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1156030135","title":"皮拉馬爾製藥解決方案宣佈與Botanix合作，支持藥物原料開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1156030135","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156030135?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 21:58","pubTimestamp":1779112695,"startTime":"0","endTime":"0","summary":"皮拉马尔制药有限公司旗下业务单元皮拉马尔制药解决方案宣布，已与Botanix Pharmaceuticals Ltd建立合作伙伴关系，旨在为其药物原料的开发工作提供支持。此项合作将整合双方的专业能力，共同推进相关药物开发项目的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7508","BK7096","BK7502"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194932028","title":"Botanix製藥與Piramal達成合作 後者將啓動Sofdra活性成分溴化索夫溴銨的開發服務並擔任替代商業供應商","url":"https://stock-news.laohu8.com/highlight/detail?id=1194932028","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194932028?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 06:53","pubTimestamp":1776293594,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited  宣布与Piramal Pharma Solutions建立重要合作伙伴关系。根据协议，Piramal将正式启动溴化索夫溴铵的开发服务，该活性药物成分是Botanix旗下创新疗法Sofdra的核心成分。此次合作标志着Piramal将成为溴化索夫溴铵的替代商业供应商，为Botanix提供关键原料的供应链保障。作为专注于皮肤病创新疗法的研发企业，Botanix通过此次合作进一步优化了其供应链体系。双方案担的协同合作，将为Sofdra未来的市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7502","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258984","title":"Botanix製藥公司獲得4000萬澳元兩輪增發堅定承諾，新股發行價每股0.06澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258984","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193258984?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 06:44","pubTimestamp":1771281854,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd（澳交所代码：BOT）宣布已成功获得总额4000万澳元的两轮增发坚定认购承诺。此次增发的新股定价为每股0.06澳元，标志着市场对该公司发展前景的强劲信心。\n这项融资计划将分两个阶段实施，旨在为公司的研发项目和运营扩张提供资金支持。每股0.06澳元的发行价反映了投资者对Botanix制药业务战略和增长潜力的认可。此次增发的顺利完成，预计将显著增强公司的资金实力，为其在制药领域的持续创新和市场拓展奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BOT.AU","BK7502"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}